Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses
Sui‐Yuan Chang, Kuo‐Yen Huang, Tai‐Ling Chao, Han-Chieh Kao, Yu-Hao Pang, Lin Lü, Chun-Lun Chiu, Hsin-Chang Huang, Ting-Jen Rachel Cheng, Jim‐Min Fang, Pan‐Chyr Yang
Abstract
(42.5 ppm) in aqueous solution was prepared and characterized by spectroscopy, transmission electron microscopy, dynamic light scattering analysis and potentiometric titration. Based on the in vitro cell-based assay, TPNT1 inhibited six major clades of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with effective concentration within the range to be used as food additives. TPNT1 was shown to block viral entry by inhibiting the binding of SARS-CoV-2 spike proteins to the angiotensin-converting enzyme 2 (ACE2) receptor and to interfere with the syncytium formation. In addition, TPNT1 also effectively reduced the cytopathic effects induced by human (H1N1) and avian (H5N1) influenza viruses, including the wild-type and oseltamivir-resistant virus isolates. Together with previously demonstrated efficacy as antimicrobials, TPNT1 can block viral entry and inhibit or prevent viral infection to provide prophylactic effects against both SARS-CoV-2 and opportunistic infections.